Operating Profitability Projected for Q3 2026 as VOQUEZNA Demand Accelerates
Phathom Pharmaceuticals (NASDAQ: PHAT) delivered a standout update with its Q4 and FY 2025 results, highlighting a dramatic revenue increase and a focused pathway to operating profitability by the third quarter of 2026. This momentum is powered by soaring adoption of VOQUEZNA, the company’s lead product for gastrointestinal (GI) conditions, and rigorous financial discipline throughout the year.
Revenue Growth and Expense Control Define 2025 Performance
Net revenues jumped 217% in FY 2025 to $175.1 million, up from $55.3 million in 2024. Q4 2025 alone delivered $57.6 million in net revenues, nearly doubling from the same period a year earlier. Meanwhile, operating expenses declined, falling to $55.9 million in Q4 2025 from $85.3 million a year earlier—underscoring improvements in cost management, especially in commercial-related and personnel expenses.
| Metric | Q4 2025 | Q4 2024 | FY 2025 | FY 2024 |
|---|---|---|---|---|
| Net Revenues ($M) | 57.58 | 29.66 | 175.11 | 55.25 |
| Operating Expenses ($M) | 55.87 | 85.27 | 312.50 | 324.75 |
| Non-GAAP Operating Expenses ($M) | 50.30 | 78.60 | 283.80 | 300.70 |
| Net Loss ($M) | (21.15) | (74.45) | (221.25) | (334.33) |
| Non-GAAP Adjusted Net Loss ($M) | (5.74) | (56.38) | (150.46) | (262.32) |
Strong VOQUEZNA Prescription Growth Fuels Top Line
More than 1.1 million VOQUEZNA prescriptions have been filled to date, including roughly 273,000 in Q4 2025—a 24% growth quarter-over-quarter. Covered prescriptions, a key revenue driver, advanced 21% in the same period. Realignment of the sales force and new marketing leadership late in 2025 further strengthen prospects for deepening penetration in the GI market.
Capital Position Enhanced by Equity Offering and Debt Modification
After raising $130 million in an equity offering in January 2026, Phathom renegotiated its term debt, lowering interest rates and extending the maturity to February 2029. Post-debt modification, the company retains about $190 million in cash—ample to meet the highest anticipated cash covenant ($120 million in 2026) and support planned growth without liquidity concerns.
| Balance Sheet Item | Dec 31, 2025 ($K) | Dec 31, 2024 ($K) |
|---|---|---|
| Cash & Cash Equivalents | 129,972 | 297,263 |
| Total Assets | 259,149 | 378,318 |
| Total Liabilities | 697,318 | 631,898 |
| Total Stockholders' Deficit | (438,169) | (253,580) |
2026 Guidance Signals Operating Profitability and Gross Margin Expansion
Management expects FY 2026 net revenues of $320–345 million, non-GAAP operating expenses of $235–250 million, and gross margins around 80%. Operating profitability, excluding non-cash stock-based compensation, is projected from Q3 and for the full year 2026—a key inflection point as Phathom bets on continued VOQUEZNA prescription momentum and cost control.
- Net revenues: $320–345 million (includes classification changes)
- Gross-to-net: 55–59%
- Gross margin: ~80%
- Non-GAAP operating expenses: $235–250 million
Clinical Pipeline Remains on Track
The ongoing Phase 2 pHalcon-EoE-201 trial for VOQUEZNA in eosinophilic esophagitis (EoE) is enrolling as planned, with topline results expected in 2027. If successful, this could further broaden VOQUEZNA’s market opportunity.
What to Watch: Key Takeaways for Investors
Phathom’s performance reflects strong execution across commercialization, cost management, and capital strategy. As VOQUEZNA adoption accelerates and operating expenses remain contained, the company’s path to profitability in 2026 looks credible. With a solid cash position, careful guidance, and ongoing R&D, investors might want to keep an eye on prescription growth, profit margins, and updates from the clinical pipeline as indicators for continued strategic progress.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI